Neuropeptide S vs Cotadutide
Head-to-head comparison of Neuropeptide S (Neuropeptide S) and Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Neuropeptide S | Cotadutide |
|---|---|---|
| Category | Cognitive Enhancement | Weight Management |
| Full Name | Neuropeptide S | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist |
| Molecular Weight | 2203 Da | ~4,700 Da |
| Half-Life | Minutes to <1 hour | Approximately 24 hours |
| Amino Acids | 20 | 37 |
| Typical Dose | Research-only; no validated human dose | 0.3-3 mg daily in clinical studies |
| Route | Intracerebroventricular/Intranasal | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 28 | 18 |
| Research Status | Pre-clinical | Clinical |
Neuropeptide S Benefits
- ✓anxiolysis
- ✓stress resilience
- ✓attention support
- ✓arousal modulation
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
Neuropeptide S Dosing
0.1-1 nmol i.c.v. in animal studies|intranasal research-only exploration|no established human protocol
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
Neuropeptide S Side Effects
- ⚠sleep disruption
- ⚠headache
- ⚠jitteriness
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Neuropeptide S
Animal studies suggest NPS can reduce anxiety-like behavior while altering wakefulness and alertness through the NPS receptor system. Human cognitive data are very limited, and it has no approved clinical indication.
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.